⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096324 | 0.65 | IKBKB (0.36) | — | |
| SCHEMBL4411541 | 0.64 | KDM4E (0.34) | — | |
| SCHEMBL569598 | 0.60 | — | — | |
| SCHEMBL1424384 | 0.60 | — | — | |
| SCHEMBL1529258 | 0.56 | — | — | |
| Hydrochloric Acid SCHEMBL22188751 | 0.54 | MASP2 (0.38) | — | |
| SCHEMBL20589156 | 0.54 | MASP2 (0.38) | — | |
| SCHEMBL9902177 | 0.51 | — | — | |
| Trifluoromethylbenzene SCHEMBL23087097 | 0.46 | — | — | |
| SCHEMBL21306240 | 0.41 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524881-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | claimed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | claimed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | claimed |
| EP-1333834-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2007-01-17 | — | — | EP | claimed |
| EP-1444223-A1 | AMINOPYRIMIDINES AND -PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | claimed |
| EP-1333834-A2 | ANTIINFLAMMATION AGENTS | Tularik Inc. (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2003048152-A2 | INFLAMMATION MODULATORS | TULARIK INC. (US) | 2003-06-12 | — | — | WO | claimed |
| WO-2003040131-A1 | AMINOPYRIMIDINES AND PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | claimed |
| WO-2002041843-A2 | ANTIINFLAMMATION AGENTS | TULARIK INC. (US) | 2002-05-30 | — | — | WO | claimed |
| EP-2597088-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-2631229-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-8673915-B2 | P 2×4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| WO-2002041843-A2 | ANTIINFLAMMATION AGENTS | TULARIK INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-0126581-B1 | ANTIFUNGAL TRIAZOLE DERIVATIVES | Pfizer Limited (GB) | 1987-06-03 | — | — | EP | disclosed |
| US-4554286-A | Antifungal 1-triazolyl-2-aryl-3-(5-trifluoromethylimidazol-1-yl)propan-2-ol derivatives | PFIZER INC. (US) | 1985-11-19 | — | — | US | disclosed |
| EP-0126581-A1 | Antifungal triazole derivatives | Pfizer Limited (GB) | 1984-11-28 | — | — | EP | disclosed |